Sensitive  ||| S:0 E:10 ||| JJ
skin  ||| S:10 E:15 ||| NN
and  ||| S:15 E:19 ||| CC
rosacea ||| S:19 E:26 ||| NNS
:  ||| S:26 E:28 ||| :
nosologic  ||| S:28 E:38 ||| FW
framework  ||| S:38 E:48 ||| FW
Flushing  ||| S:48 E:57 ||| FW
due  ||| S:57 E:61 ||| JJ
to  ||| S:61 E:64 ||| TO
rosacea  ||| S:64 E:72 ||| NNS
may  ||| S:72 E:76 ||| MD
be  ||| S:76 E:79 ||| VB
mistaken  ||| S:79 E:88 ||| VBN
for  ||| S:88 E:92 ||| IN
sensitive  ||| S:92 E:102 ||| JJ
skin ||| S:102 E:106 ||| NN
,  ||| S:106 E:108 ||| ,
which  ||| S:108 E:114 ||| WDT
can  ||| S:114 E:118 ||| MD
manifest  ||| S:118 E:127 ||| VB
as  ||| S:127 E:130 ||| IN
abnormal  ||| S:130 E:139 ||| JJ
sensations  ||| S:139 E:150 ||| NN
during  ||| S:150 E:157 ||| IN
fairly  ||| S:157 E:164 ||| RB
acute  ||| S:164 E:170 ||| JJ
reactions  ||| S:170 E:180 ||| NNS
to  ||| S:180 E:183 ||| TO
a  ||| S:183 E:185 ||| DT
variety  ||| S:185 E:193 ||| NN
of  ||| S:193 E:196 ||| IN
triggers ||| S:196 E:204 ||| NN
,  ||| S:204 E:206 ||| ,
many  ||| S:206 E:211 ||| JJ
of  ||| S:211 E:214 ||| IN
which  ||| S:214 E:220 ||| WDT
are  ||| S:220 E:224 ||| VBP
shared  ||| S:224 E:231 ||| VBN
by  ||| S:231 E:234 ||| IN
rosacea  ||| S:234 E:242 ||| NN
and  ||| S:242 E:246 ||| CC
sensitive  ||| S:246 E:256 ||| JJ
skin ||| S:256 E:260 ||| NN
.  ||| S:260 E:262 ||| .
Nevertheless ||| S:262 E:274 ||| RB
,  ||| S:274 E:276 ||| ,
the  ||| S:276 E:280 ||| DT
two  ||| S:280 E:284 ||| CD
conditions  ||| S:284 E:295 ||| NNS
are  ||| S:295 E:299 ||| VBP
clearly  ||| S:299 E:307 ||| RB
different ||| S:307 E:316 ||| JJ
.  ||| S:316 E:318 ||| .
Rosacea  ||| S:318 E:326 ||| NNP
is  ||| S:326 E:329 ||| VBZ
a  ||| S:329 E:331 ||| DT
vascular  ||| S:331 E:340 ||| JJ
disease ||| S:340 E:347 ||| NN
,  ||| S:347 E:349 ||| ,
worsens  ||| S:349 E:357 ||| VBD
gradually  ||| S:357 E:367 ||| RB
over  ||| S:367 E:372 ||| IN
time ||| S:372 E:376 ||| NN
,  ||| S:376 E:378 ||| ,
manifests  ||| S:378 E:388 ||| VBG
as  ||| S:388 E:391 ||| IN
flares  ||| S:391 E:398 ||| NN
triggered  ||| S:398 E:408 ||| VBD
chiefly  ||| S:408 E:416 ||| RB
by  ||| S:416 E:419 ||| IN
systemic  ||| S:419 E:428 ||| JJ
factors ||| S:428 E:435 ||| NNS
,  ||| S:435 E:437 ||| ,
is  ||| S:437 E:440 ||| VBZ
largely  ||| S:440 E:448 ||| RB
confined  ||| S:448 E:457 ||| VBN
to  ||| S:457 E:460 ||| TO
the  ||| S:460 E:464 ||| DT
facial  ||| S:464 E:471 ||| JJ
and ||| S:471 E:474 ||| CC
/ ||| S:474 E:475 ||| NNP
or  ||| S:475 E:478 ||| CC
ocular  ||| S:478 E:485 ||| JJ
regions ||| S:485 E:492 ||| NNS
,  ||| S:492 E:494 ||| ,
and  ||| S:494 E:498 ||| CC
responds  ||| S:498 E:507 ||| VBZ
to  ||| S:507 E:510 ||| TO
specific  ||| S:510 E:519 ||| JJ
treatments ||| S:519 E:529 ||| NNS
.  ||| S:529 E:531 ||| .
Sensitive  ||| S:531 E:541 ||| JJ
skin ||| S:541 E:545 ||| NN
,  ||| S:545 E:547 ||| ,
in  ||| S:547 E:550 ||| IN
contrast ||| S:550 E:558 ||| NN
,  ||| S:558 E:560 ||| ,
is  ||| S:560 E:563 ||| VBZ
an  ||| S:563 E:566 ||| DT
epidermal  ||| S:566 E:576 ||| JJ
cosmetic  ||| S:576 E:585 ||| JJ
problem  ||| S:585 E:593 ||| NN
that  ||| S:593 E:598 ||| WDT
runs  ||| S:598 E:603 ||| VBZ
a  ||| S:603 E:605 ||| DT
variable  ||| S:605 E:614 ||| JJ
course ||| S:614 E:620 ||| NN
,  ||| S:620 E:622 ||| ,
with  ||| S:622 E:627 ||| IN
diffuse  ||| S:627 E:635 ||| JJ
skin  ||| S:635 E:640 ||| NN
involvement  ||| S:640 E:652 ||| NN
and  ||| S:652 E:656 ||| CC
flares  ||| S:656 E:663 ||| NNS
triggered  ||| S:663 E:673 ||| VBD
mainly  ||| S:673 E:680 ||| RB
by  ||| S:680 E:683 ||| IN
contact  ||| S:683 E:691 ||| NN
factors ||| S:691 E:698 ||| NNS
.  ||| S:698 E:700 ||| .
The  ||| S:700 E:704 ||| DT
flares  ||| S:704 E:711 ||| JJ
respond  ||| S:711 E:719 ||| NN
to  ||| S:719 E:722 ||| TO
specific  ||| S:722 E:731 ||| JJ
cosmetics  ||| S:731 E:741 ||| NNS
and  ||| S:741 E:745 ||| CC
are  ||| S:745 E:749 ||| VBP
usually  ||| S:749 E:757 ||| RB
worsened  ||| S:757 E:766 ||| VBN
by  ||| S:766 E:769 ||| IN
treatments  ||| S:769 E:780 ||| NNS
for  ||| S:780 E:784 ||| IN
rosacea ||| S:784 E:791 ||| NN
.  ||| S:791 E:793 ||| .
